Login to Your Account


Hyperglycemia eclipses promising PFS data for Clovis' CO-1686

By Jennifer Boggs
Managing Editor

Monday, June 2, 2014
Elevated glucose levels emerging in roughly one-fourth of lung cancer patients receiving Clovis Oncology Inc.'s next-generation EGFR inhibitor CO-1686 may have overshadowed the promising interim progression-free survival (PFS) rate presented at the American Society of Clinical Oncology meeting over the weekend, at least on Wall Street, but analysts say the targeted covalent inhibitor remains a contender against Astrazeneca plc's AZD9291.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription